US FDA approves Springworks' genetic disorder drug
ReutersFeb 11, 2025 8:57 PM
Feb 11 (Reuters) - The U.S. Food and Drug Administration on Tuesday approved Springworks Therapeutics' SWTX.O drug to treat a type of rare genetic disorder that causes tumors to grow on nerves throughout the body.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
What to Watch in Nvidia’s Q2 FY2026 Earnings: AI Growth, Margins, and Market Impact
TradingKey - NVIDIA Corporation (NASDAQ: NVDA) will report its Q2 FY2026 earnings on Wednesday, August 27, 2025, after the U.S. market closes. The earnings call is scheduled for 5:00 p.m. Eastern Time. With Nvidia being a bellwether in AI, gaming, and data center markets, and carrying significant...TradingKey
10 hours ago
U.S. July PCE and Q2 GDP Preview: With Rate Cuts Looming, Will U.S. Stocks Continue to Rise?
TradingKey - On 28-29 August 2025, the U.S. will release July PCE and Q2 GDP data. Market expectations suggest both headline and core PCE will rise 0.3% month-over-month, consistent with June figures. For growth, in line with the preliminary estimate on 30 July, the revised Q2 annualised real GDP grTradingKey
10 hours ago
U.S. Dollar Index: Assessing Its Future Trend Through Macro Analysis of the U.S., Eurozone, Japan, and U.K.
TradingKey - Looking ahead, in the U.S., slowing economic growth combined with ongoing interest rate cuts will exert downward pressure on the dollar. In the Eurozone, weak economic performance and continued ECB rate cuts will likely depreciate the euro, indirectly supporting the U.S. Dollar Index...TradingKey
16 hours ago
Powell's Jackson Hole Speech: For U.S. Stocks, Hawk or Dove Signal Could Be a Lose-Lose?
TradingKey - As U.S. inflation and labor market data show signs of rebalancing, Treasury traders and Wall Street banks have largely priced in a rate cut at the September FOMC meeting — the first of 2025. Yet both a more dovish-than-expected tone and a potential surprise hawkish signal from Fed ChairTradingKey
Mon, Aug 18
Eurozone Q2 GDP Commentary: Will the Euro's Upward Momentum Persist?
TradingKey - On 14 August 2025, Eurostat published Q2 GDP figures, revealing a drop in the Eurozone's quarter-on-quarter growth from 0.6% in the first quarter to 0.1%. Consequently, annual growth eased from 1.5% to 1.4%. The slowdown primarily stems from the diminishing boost from European...TradingKey
Mon, Aug 18
